Figure 1From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusFrequency comparison of BILAG B- and C-level activities for each body system at screening, 6, 10 and 18 weeks.Back to article page